Bayer (BAYN) Stock Rating Reaffirmed by Citigroup

Citigroup reiterated their buy rating on shares of Bayer (FRA:BAYN) in a research report sent to investors on Thursday morning.

Other equities research analysts also recently issued research reports about the stock. Warburg Research set a €121.00 ($144.05) price target on shares of Bayer and gave the stock a buy rating in a research note on Wednesday, August 23rd. Jefferies Group set a €137.00 ($163.10) price target on shares of Bayer and gave the stock a buy rating in a research note on Wednesday, August 23rd. Commerzbank set a €124.00 ($147.62) price target on shares of Bayer and gave the stock a buy rating in a research note on Monday, August 28th. UBS set a €125.00 ($148.81) price target on shares of Bayer and gave the stock a buy rating in a research note on Wednesday, August 23rd. Finally, Deutsche Bank set a €124.00 ($147.62) price target on shares of Bayer and gave the stock a buy rating in a research note on Monday, August 28th. One analyst has rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the company. Bayer presently has an average rating of Buy and a consensus target price of €122.19 ($145.46).

Bayer (FRA:BAYN) opened at €105.50 ($125.60) on Thursday. Bayer has a one year low of €90.26 ($107.45) and a one year high of €123.82 ($147.40).

TRADEMARK VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/11/bayer-bayn-stock-rating-reaffirmed-by-citigroup.html.

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply